MPLT

MapLight Therapeutics

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

06/25/26

Business Summary

MapLight Therapeutics operates as a clinical-stage biotechnology company focused on developing novel therapies, monetizing value primarily through drug development milestones, partnerships, and eventual commercialization rights. Cash generation is currently absent at the operating level, so shareholder value depends on successful progression of drug candidates through trials that can unlock licensing deals or equity re-rating events. The competitive moat, if realized, would stem from proprietary compounds, intellectual property protection, and regulatory exclusivity rather than scale or margin strength. In biotechnology, durable advantage is built on differentiated clinical data and patent protection, not current profitability, meaning the company’s moat is entirely pipeline-contingent rather than financially entrenched today.

 


Analyze MPLT on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$1,134

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

2.5

EV / EBITDA

-5

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$18.56

Next Year EPS Growth Estimate

-$3.74

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-35.20%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

-

Altman Z-Score

30.7

Return on Invested Capital (ROIC)

-120.30%

Current Ratio

20

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze MPLT on TradingView

Gainseekers Quantitative Analysis

Summary

The company is a $1,134M biotechnology business with no earnings, no forward P/E, EPS of -5, and estimated EPS next year of -$18.56, which immediately disqualifies it from any traditional GARP framework. Operating margin of -35.20% and ROIC of -120.30% confirm that capital is being destroyed at an aggressive rate, not merely reinvested. However, the Altman Z-Score of 30.7 and a current ratio of 20 indicate extreme balance sheet safety and virtually no near-term solvency risk, meaning bankruptcy risk is minimal despite heavy losses. This is not a mispriced compounder; it is a highly speculative clinical-stage asset where valuation rests entirely on future pipeline outcomes rather than financial performance.

AI Exposure / Tech Reliance

As a Biotechnology company within Healthcare, it operates in an industry increasingly shaped by AI-driven drug discovery, biomarker identification, and clinical trial optimization. The sector structurally benefits from computational biology and machine learning integration, which can compress development timelines and improve target precision. However, financial data provided shows no evidence yet of operating leverage or profitability from such technological integration.

The Bull Case

A value-oriented investor could argue that a $1,134M market cap combined with an Altman Z-Score of 30.7 and a current ratio of 20 signals exceptional financial durability for a pre-profit biotech. Institutional ownership at 32.67% suggests credible capital is involved, and a consensus rating of 3.10% indicates at least moderate analyst engagement. The absence of debt metrics and a zero dividend policy implies capital is being preserved for reinvestment rather than servicing liabilities or distributing cash. For a GARP investor willing to underwrite near-term losses, the balance sheet strength provides a long runway to clinical inflection points, which is often the critical variable in biotechnology upside scenarios.

The Bear Case

The bear case is overwhelming from an operating standpoint: EPS of -5 deteriorating to an estimated -$18.56 next year signals accelerating losses, not narrowing ones. Operating margin of -35.20% and ROIC of -120.30% show deeply negative capital efficiency, meaning every incremental dollar invested is currently destroying value. There is no Price/Earnings, no Forward P/E, no PEG Forward, no Return on Equity, no Debt/Equity, no Short % of Float, and no Piotroski F-Score provided, leaving major analytical blind spots and suggesting an inability to frame valuation through traditional metrics. Sales Growth Next Year of -$3.74 further reinforces contraction rather than expansion, making this structurally a binary, pipeline-dependent equity rather than an investable operating business.

Market Sentiment & Smart Money

Short Interest %

3.10%

Analyst Consensus

1.38

Average Analyst Price Target

$32.67

Institutional Ownership %

52.50%

1-Year Beta

1.13

Insider Buying % (6 Mo)

52.30%%

Distance to 52-Week High

88.30%

Distance to 52-Week Low

218.40%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.